Small study tests rituximab against rare vessel disease
NCT ID NCT03920722
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tested whether the drug rituximab, given with steroids, works better than steroids alone for people with a rare disease called microscopic polyangiitis that inflames small blood vessels. Only 8 patients took part, and the goal was to see if the combination could prevent relapses. Because the study is so small, the results are not conclusive.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- rituximab
- What this could lead to
- If successful, this could point toward a more effective treatment for microscopic polyangiitis, reducing relapses.
- What could go wrong
- This is a very small, completed phase 3 trial with only 8 participants, so results may not apply broadly. Rituximab can cause infusion reactions and increase infection risk.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MICROSCOPIC POLYANGIITIS (MPA) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Cochin Hospital
Paris, 75014, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New study aims to spot eye damage early in rare vasculitis patients
- Can early rituximab stop vasculitis relapses? new study aims to find out
- Pregnancy and vasculitis: new study seeks answers
- Could a 4-Week steroid course be safer for vasculitis patients?
- Skin biopsies shed light on rare blood vessel disease